Vijay Kasturi retweeted
Today we reported financial results for the third quarter ended September 30, 2026, and provided business updates.
Details: bit.ly/4sMtWSi
#Urology #NMIBC #CGON
Vijay Kasturi retweeted
The BCAN Think Tank provided an invaluable forum to share and learn the latest innovations in the bladder cancer space. Thanks to @UroDocAsh and @UrogerliMD for sharing this promising early data on intravesical cretostimogene and systemic nivolumab.
#BladderCancer #BCANTT26
Proud to see @UrogerliMD pushing the field into new territory.
Combining intravesical cretostimogene with systemic nivolumab in cisplatin-ineligible MIBC, a phase 1b showing no DLTs, no new safety signals, and a 42.1% pCR rate in the per protocol population.
Congratulations, Roger. Excellent work.
#BladderCancer #BCANTT26 @IBCG_BladderCA @shilpaonc @SpiessPhilippe @UTMDAnderson
@PGrivasMDPhD @JoshMeeks @djmcconkey
Check out my latest article: Celebrating an Important Milestone for the Bladder Cancer Community: BOND-003 Results Published in The Lancet linkedin.com/pulse/celebrati… via @LinkedIn
Vijay Kasturi retweeted
BOND-003 Cohort C data in @TheLancetOncol
A 75% CR rate at any time, with a median follow-up of 25.8 months and no grade 3/4 treatment-related adverse events, represents an important contribution to the evolving treatment landscape for BCG-unresponsive NMIBC.
Advances like this don’t happen overnight. They are built on patients willing to participate, investigators who believe early, committed clinical teams, and industry partners who stay the course.
Science is a team sport. Congratulations to everyone involved.
sciencedirect.com/science/ar…
@MarkTysonMD @UrogerliMD @garysteinbergmd @tbivala1 @JamesBurke34034 @cgoncology @KuanArthur @IBCG_BladderCA
Vijay Kasturi retweeted
1/ BOND-003 Cohort C now out in @TheLancetOncol: Ph3 creto monotherapy for HR BCG-u #bladdercancer with CIS. Details below 👇@MayoUrology @MayoClinic @cgoncology @UrogerliMD @garysteinbergmd @tbivala1 @KuanArthur #EdUchio #NealShore @jamesburke34034 authors.elsevier.com/a/1nVzi…
Vijay Kasturi retweeted
We are pleased to announce that results from the Phase 3 BOND-003 Cohort C trial have been published in The Lancet Oncology. This peer-reviewed publication details the study's clinical findings regarding complete response rates, duration of response, and the safety profile observed in patients with high-risk, BCG-unresponsive NMIBC with carcinoma in situ. We are incredibly grateful to the patients, investigators, and clinical teams who made this research possible. Read our full press release here: ir.cgoncology.com/news-relea… #BladderCancer #NMIBC
Vijay Kasturi retweeted
We are thrilled to welcome David Fela to the CG Oncology team as our new Vice President, Analytical Development and Quality Control.
As we advance our clinical programs toward potential commercialization, maintaining rigorous analytical and quality standards is paramount. David brings over two decades of technical leadership in biopharma, with deep expertise in CMC strategy and scaling QC operations. His experience in navigating complex regulatory submissions and building high-performing teams will be invaluable as we continue our mission to deliver transformative therapies to the bladder cancer community.
Welcome aboard, David!
#NewHire #LeadershipSpotlight #LifeAtCG
Vijay Kasturi retweeted
For #NationalCancerSurvivorMonth, we honor the strength and resilience of cancer survivors everywhere.
For many patients with bladder cancer, survivorship is an ongoing journey—marked by the risk of recurrence and the anxiety of what comes next.
At CG Oncology, we’re committed to advancing bladder-sparing treatment candidates like cretostimogene, so patients have better options and more hope for the future.
Vijay Kasturi retweeted
We’re honored to contribute to today's conversation at the 2026 ASCO Genitourinary (GU) Cancers Symposium with five posters featuring cretostimogene across the Non-Muscle Invasive Bladder Cancer (NMIBC) landscape.
View the posters here: cgoncology.com/abstracts-and…
#BladderCancer #Urology #UroOncology
Vijay Kasturi retweeted
Today Colin Dinney, MD, of @MDAndersonNews shared some exclusive insights on updated data from the BOND-003 and CORE-001 trials of cretostimogene grenadenorepvec in BCG-unresponsive NMIBC! Check back at onclive.com to learn more! @AmerUrological #AUA25 #blcsm
Vijay Kasturi retweeted
There were ~83,000 new cases of #bladdercancer in the U.S. in 2024.
Our investigational drug, cretostimogene grenadenorepvec, is designed to treat patients with BCG-unresponsive #NMIBC – which represents 75% of all new bladder cancer cases.
Learn more: bit.ly/48IZnmi
Vijay Kasturi retweeted
We're pleased to announce @CGOncology's Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. bit.ly/3Rv5a7C
Vijay Kasturi retweeted
#ASCO24 CORE-001: Ph 2, single arm study of Creto + Pembro in BCG-UR, NMIBC w/ CIS @UrogerliMD @urotoday @cgoncology
⚡️n=35
⚡️CR rate 12 mo: 57.1%
⚡️CR rate 24 mo: 54.3%
⚡️CR rate any time: 82.9%
⚡️95.1% of CRs @ 12 mo remain in CR @ 24 mo
⚡️12 mo landmark RFS: 77.3%
⚡️24 mo landmark RFS: 69.6%
⚡️100% PFS, no progression to MIBC or mUC
⚡️12 mo landmark DoR: 81.6%
⚡️24 mo landmark DoR: 77.3%
Vijay Kasturi retweeted
Great results from this combination! The best benefit (to risk) from systemic checkpoint inhibition I have seen yet for NMIBC
Incredible work by @UrogerliMD with truly impressive results - cretostimogene + pembrolizumab for #bcgunresponsive #NMIBC with impressive durability: 95% of CRs at 12 mos maintained at 24 mos @MoffittNews @cgoncology @garysteinbergmd
Vijay Kasturi retweeted
Today at #ASCO24: In a phase 2 trial evaluating intravesical delivery of an oncolytic adenovirus + anti-PD-1 in patients with BCG unresponsive, non-muscle invasive #BladderCancer, the complete response rate at 12 months was 57.1% @UrogerliMD doi.org/10.1038/s41591-024-0…
Vijay Kasturi retweeted
🏙 Heading to #ASCO24? Our #patientcentric approach addresses all stages of #bladdercancer w/innovative #immunotherapies. Hear the final results of our CORE-001 Phase 2 trial, showcasing our commitment to improving patient outcomes & transforming care.
🔗 bit.ly/3QZhf4T
Vijay Kasturi retweeted
Excited to announce we have received both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive #BladderCancer
Read the full release:
businesswire.com/news/home/2…
Vijay Kasturi retweeted
Updated results from #CORE1 using pembro + cretostimogene (cg0070) in BCG unresponsive CIS
👉 Overall CR = 85% (29/34)
👉CR @ 12 months = 68% (17/25)
👉AE profile similar to monotherapy trials
@garysteinbergmd @UroDocAsh @tbivala1 @cgoncology
onclive.com/view/phase-2-dat… – at Tampa, FL
